• Palgic.com
    Product website
  • Important Announcement
    PALGIC® is the only product containing carbinoxamine that has been approved by the FDA. All other carbinoxamine-containing products are not FDA approved and contain labeling and dosing information that has not been approved by FDA. These products are being illegally marketed.
  • Package Insert
    Please see package insert for full prescribing details
  • Carbinoxamine.com
    This site contains historical reference information on Carbinoxamine Maleate.

Palgic®

Palgic® is effective.

A wide range of allergy patients get excellent antihistamine relief with carbinoxamine maleate, the active ingredient in Palgic®. Carbinoxamine maleate has been prescribed by doctors for more than 50 years. It is very well tolerated while delivering a powerful anticholinergic (drying) benefit and a strong H1 histamine block.

Patient's get relief in as little as 30 minutes and many will only need one 4mg tablet or 4mg/5mL liquid dose to enjoy a symptom-free, active day. The primary side effect is a 15-20% sedation rate.

Palgic® is indicated for:

  • Seasonal allergic rhinitis
  • Perennial allergic rhinitis
  • Vasomotor rhinitis
  • Allergic conjunctivitis (due to inhalant allergens and food)
  • Urticaria (cases of mild, uncomplicated allergic skin manifestations)
  • Angioedema (cases of mild, uncomplicated allergic skin manifestations)
  • Dermatographism
  • Anaphylactic reaction therapy adjunctive to epinephrine
  • Amelioration of the severity of allergic reactions to blood or plasma

Palgic® is indicated for the effective relief of allergy symptoms caused by seasonal and perennial allergic rhinitis.

More from our Product Family
  • Panlor® SS & Panlor® DC: Indicated for the analgesic relief of moderate to moderately severe pain. Each dose contains an effective triad formula of dihydrocodeine, acetaminophen and caffeine.
  • Cerefolin®NAC: for the dietary management of hyperhomocysteinemia; particularly for individuals diagnosed with or at risk for mild to moderate cognitive impairment, vascular dementia, or Alzheimer's disease.